Interim results from a phase 3 Ebola vaccine study in Guinea.
Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA. Electronic address: philip.krause@fda.hhs.gov.
Philip R
PR
Krause
D046129:Ebola Vaccines; D005260:Female; D019142:Hemorrhagic Fever, Ebola / Q000517:prevention & control*; D006801:Humans; D008297:Male
D046129:Ebola Vaccines